Search Results for: 19

— Initiated Phase 2 for Prevention of C. difficile, Expected to Initiate Phase 2 for IBS-C by end of June 2015, and Expanded Leadership Team as Company Moves into Next Development Stage — — Conference Call Today, May 11, 2015, at 4:30 p.m. EDT — ROCKVILLE, Md., May 11, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE […]

— Appointment Reflects Company’s Expanded Clinical and Market Driven Focus — ROCKVILLE, Md., May 7, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, announced Maureen Early joined the team in the newly created position of Vice President, Commercial. In her

— Executive Brings Significant Biotech Industry Leadership Experience to Team as Company Enters Next Phase of Development — ROCKVILLE, Md., May 4, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapeutics focused on protecting the microbiome, as well as treating other diseases, announced Steven A. Shallcross has been appointed Chief Financial

— Results Provide Support for Advancing SYN-005 into Clinic — ROCKVILLE, Md., April 27, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced that preclinical data from its novel SYN-005 program for the treatment of Pertussis were presented

— Data Supporting Development of Expanded C. difficile Preventive Therapeutics also Accepted for Presentation — ROCKVILLE, Md., April 1, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that clinical data supporting the development of SYN-004,

— Study Advances Development of Preventive Approach for C. difficile Infection — ROCKVILLE, Md., March 30, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced the initiation of a Phase 2a clinical trial to evaluate the

— Supportive Evidence for No Active Enzyme Absorption into Bloodstream Observed in Phase 1 Studies — — Results Pave Way for Phase 2a Clinical Trial to Start this Month — ROCKVILLE, Md., March 19, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a

— Steady Progress in All Programs; Two Phase 2 Clinical Trials to Start in 2015 — — Conference Call Today, March 16, 2015, at 8:30 a.m. (ET) — ROCKVILLE, Md., March 16, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting

ROCKVILLE, Md., March 11, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that preclinical results supporting the development of SYN-004, the Company’s candidate therapy designed to degrade intravenous (IV) antibiotics within the gastrointestinal (GI) tract and

— Conference Call Scheduled for Monday, March 16, 2015, at 8:30 a.m. EDT — ROCKVILLE, Md., March 9, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that the Company intends to release its financial results for the